Cost-Effectiveness of Resistance Guided Therapy for Mycoplasma Genitalium for Women, Men Who Have Sex with Men (MSM) and Men Who Have Sex with Women (MSW) in Australia
Rabiah Adawiyah,Lenka A. Vodstrcil,Catriona Bradshaw,Christopher K. Fairley,Lei Zhang,Jason Ong
DOI: https://doi.org/10.2139/ssrn.4673221
2023-01-01
Abstract:Background: The recommended first-line treatment for Mycoplasma genitalium infections is azithromycin. However, the prevalence of macrolide resistance for M. genitalium has increased from 10% to more than 50% worldwide in the past decade. In 2013, Australia introduced a resistance-guided therapy (RGT) strategy to manage M. genitalium infections. This study assesses the cost-effectiveness of the RGT approach compared to no RGT in women, men who have sex with men (MSM), and men who have sex with women (MSW) in Australia.Methods: We constructed dynamic transmission models of M. genitalium infections in women, MSM, and MSW in Australia, each with a population of 100,000. These models compared the costs and quality-adjusted life-years (QALYs) gained between RGT and no RGT scenarios from a healthcare perspective over ten years, used a 3% annual discount rate and willingness-to-pay threshold of AU$ 50,000. All costs are reported in 2022 Australian dollars.Findings: Over ten years, without RGT, there will be 1,210, 1,074, and 2,865 symptomatic M. genitalium infections in cohorts of 100,000 women, MSM, and heterosexual men in Australia, respectively. In our model, RGT is cost-saving in women and MSM, yielding lower costs and higher QALYs than no RGT, with incremental net monetary benefit (NMB) of AU$ 10.1 million and AU$ 200,000, respectively. In MSW, the RGT approach is cost-effective, with an incremental cost-effectiveness ratio of $1,139 per QALY gained.Interpretation: RGT is cost-saving compared to no RGT for M. genitalium infections in women and MSM, and cost-effective for MSW in Australia, supporting its recommendation as the first-line national management strategy.Funding: JO receives funding from the Australian National Health and Medical Research Council Emerging Leadership Investigator Grant (GNT1193955). CB and CKF receive funding from the Australian National Health and Medical Research Council Leadership Investigator Grant (GNT1173361 and GNT1172900 respectively).Declaration of Interest: RA declare no competing interests. JO, CB and CKF reports financial support was provided by Australian National Health and Medical Research Council. CB receives federal funding from an Australian Research Council Industrial Research Transformation Hub grant and her institution has received diagnostic kits for research on M. genitalium from both Speedx pty ltd and Cepheid Pty Ltd.